Reconciling model predictions with low reported cases of COVID-19 in Sub-Saharan

Africa: Insights from Madagascar

Authors: Michelle V. Evans[1], Andres Garchitorena[2,3], Rado J.L. Rakotonanahary[3], John M.

Drake[1], Benjamin Andriamihaja[3,4], Elinambinina Rajaonarifara[2,3,5] , Calistus N. Ngonghala[6],

Benjamin Roche[2,7,8], Matthew H. Bonds[3,9], Julio Rakotonirina[10]

Affiliations:

[1] University of Georgia, Athens, GA USA

[2] Université Montpellier, CNRS, IRD, Montpellier, France

[3] PIVOT, Ranomafana, Madagascar

[4] Madagascar Institut pour la Conservation des Ecosystèmes Tropicaux, Antananarivo,

Madagascar

[5] Sorbonne Universite, Paris, France

[6] University of Florida, Gainesville, FL, USA

[7] IRD, Sorbonne Université, UMMISCO, F-93143, Bondy, France

[8] Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México

[9] Harvard Medical School, Boston, MA, USA

[10] University of Antananarivo, Antananarivo, Madagascar

Abstract:
The COVID-19 pandemic has wreaked havoc globally, and there has been a particular concern
for sub-Saharan Africa (SSA), where models suggest that the majority of the population will
become infected. Conventional wisdom suggests that the continent will bear a higher burden of
COVID-19 for the same reasons it suffers high burdens of other infectious diseases: ecology,
socio-economic conditions, lack of water and sanitation infrastructure, and weak health systems.
However, so far SSA has reported lower incidence and fatalities compared to the predictions of
standard models and the experience of other regions of the world. There are three leading
explanations, each with very different implications for the final epidemic burden: (1) low case
detection, (2) differences in COVID-19 epidemiology (e.g. low R_0), and (3) policy interventions.
The low number of cases to date have led some SSA governments to relax these policy
interventions. Will this result in a resurgence of cases? To understand how to interpret the lower-
than-expected COVID-19 case data in Madagascar, we use a simple age-structured model to
explore each of these explanations and predict the epidemic impact associated with them. We
show that the current incidence of COVID-19 cases can be explained by any combination of the
late introduction of first imported cases, early implementation of non-pharmaceutical interventions
(NPIs), and low case detection rates. This analysis reinforces that Madagascar, along with other
countries in SSA, remains at risk of an impending health crisis. If NPIs remain enforced, up to
50,000 lives may be saved. Even with NPIs, without vaccines and new therapies, COVID-19 could
infect up to 30% of the population, making it the largest public health threat in Madagascar until
early 2021.
40
Résumé:
La pandémie de COVID-19 a eu des conséquences néfastes partout dans le monde, et il y a une
préoccupation particulière pour l'Afrique subsaharienne (ASS), où des modèles suggèrent que la
majorité de la population sera infectée. Il est craint que le continent supportera un fardeau plus
élevée de COVID-19 pour les mêmes raisons qu'il souffre d'avantage d'autres maladies
infectieuses: écologie, conditions socio-économiques, manque d'infrastructures d'eau et
d'assainissement, et faiblesse des systèmes de santé. Cependant, jusqu'à présent, l'ASS a
rapporté une incidence et une mortalité bien inférieure à celle des prévisions des modèles pour
cette région, ainsi qu'au nombre observé dans d'autres régions du monde. Il y a trois explications
principales pour ce phénomène, chacune ayant des implications très différentes pour le fardeau
épidémique final: (1) détection faible des cas, (2) différences dans l'épidémiologie COVID-19 (par
exemple faible R0), et (3) interventions et politiques mises en place. Le faible nombre de cas à

ce jour a conduit certains gouvernements d'ASS à assouplir ces interventions. Cela entraînera-t-

il une résurgence de cas? Pour comprendre comment interpréter le fait que les cas COVID-19

rapportés sont plus faibles que prévu à Madagascar, nous utilisons un modèle de transmission

structuré par groupe d'âge pour explorer chacune de ces explications et prédire l'impact

épidémique qui leur est associé. Nous montrons que l'incidence actuelle des cas de COVID-19

peut s'expliquer par l'effet cumulé de l'introduction tardive des premiers cas importés, la mise en

œuvre rapide d'interventions non pharmaceutiques (INP) et de faibles taux de détection des cas.

Cette analyse renforce le fait que Madagascar, ainsi que d'autres pays d'Afrique subsaharienne,

reste à risque d'une crise sanitaire imminente. Si les INP restent appliqués, jusqu'à 50 000 vies

pourraient être sauvées. Même avec des INP, tant qu'il n'y aura pas des vaccins ni des nouvelles

thérapies efficaces, COVID-19 pourrait infecter jusqu'à 30% de la population, ce qui constituerait

la plus grande menace pour la santé publique à Madagascar jusqu'au début de 2021.

Summary Box:

● The lower-than-expected number of reported cases of COVID-19 in Madagascar can be

explained by a combination of the relatively late introduction of the disease, low detection

rates, and low transmission rates due to the early and effective implementation of non-

pharmaceutical interventions that reduced contact rates.

● Even if non-pharmaceutical interventions remain in place at current levels, COVID-19 will

be the leading cause of death due to infectious disease in Madagascar over the next year.

● Health systems in SSA remain at risk of an impending health crisis due to COVID-19.

Introduction

The COVID-19 pandemic has killed hundreds of thousands of people, collapsing health systems and economies around the world. Most models predict that without intervention, the majority of the global population will become infected and tens of millions will die as a result of the pandemic [1]. There have been particular concerns for sub-Saharan Africa (SSA) [2–4], as the major factors that drive high burdens of other infectious diseases, such as the environmental and socio-economic conditions, lack of water and sanitation infrastructure, and weak health systems, are equally relevant to the threat of COVID-19. However, so far, the perceived burden of COVID-19 in SSA is low compared to expectations both from epidemiological models and from epidemic patterns in other regions of the world [5,6]. Though SSA comprises 11% of the global population, it has only 3.6% of the total global COVID-19 incidence, much of which is due to case reports from South Africa [7]. As of July 2020, most SSA countries are reporting fewer than 100 new cases daily [8]. There are three leading potential explanations for the lower observed burden of COVID-19 in SSA: 1) low case detection, 2) region-specific epidemiology (e.g., different R_0), and 3) early implementation of effective policy interventions. The important difference among these alternative explanations is that explanations based on low case detection and effective interventions imply that there will be a major resurgence if interventions are relaxed, while explanations based on region-specific epidemiology allow for a safe reopening.

The lower-than-expected number of reported cases may be due to low detection and reporting rates. RT-PCR laboratory capacity in SSA is limited [9] and many countries have among the lowest testing rates in the world [8]. Moreover, health care access for fever and respiratory infections is low [10], which means that many symptomatic cases will not be detected, and the stigma associated with COVID-19 could further reduce health-seeking behaviors [11].

The epidemiology-based explanations for low COVID-19 cases are based on considerations of well-established factors: warmer climates, younger age distributions, and lower contact rates due to lower population density and transportation infrastructure in rural areas [12,13]. In addition, there is considerable interest in the potential immune-mediated consequences from living in a system with greater exposure to other infectious diseases and related prophylaxis and therapeutics [14]. For example, there are major trials underway on the effects of trained immunity due to the BCG vaccine, which may increase innate immunity against a range of respiratory infections [15]. However, many of these hypotheses have recently come into doubt. The pandemic phase of COVID-19 is driven by high susceptibility, not climate [16], suggesting that warmer, humid climates will not decrease transmission at this time. Further, past outbreaks of influenza, including the 1968 pandemic and 2009 H1N1 outbreak, spread throughout

the African continent and were not limited by sparse transportation networks [17]. Explanations

based in region-specific epidemiology are therefore only weakly supported.

The policy response in Africa has also been a source of considerable optimism [5,18].

African governments implemented early and strong non-pharmaceutical intervention (NPI)

policies that may have effectively contained disease transmission [5,19]. The first case of COVID-

19 was reported in SSA one month later than the first cases in Europe, allowing countries to

prepare and implement NPIs, particularly lockdowns, social distancing, masks, and regulated

domestic travel, during the early stages of the pandemic [3,19,20]. Beginning in June, several

SSA countries began relaxing lockdown NPIs in response to the economic and social costs of

lockdown given the low reported case numbers. As partial lockdowns have been lifted, some

countries' case rates have remained stable, while others have begun to increase, leading to the

WHO to urge caution and emphasize the need for a gradual and conservative release of

confinement measures in SSA [21].

It remains unknown whether SSA-specific conditions will result in different epidemic

dynamics in SSA than elsewhere, and whether the current lower-than-expected case burdens

can be explained solely by detection rates and policies. To explore these issues, we compare

COVID-19 reported case data with predictions from a simple *SEIR* compartmental model for

Madagascar that integrates age-structured social contact matrices and fatality rates, assuming

an R_0 of 2.5 [22–24] (Appendix I). We then consider what levels of detection or NPI effectiveness

could explain the current state of the epidemic, and whether those levels are plausible given

Madagascar's policies, demographics, and environmental context. Finally, based on these

explanations, we investigate possible transmission scenarios for the first year of the epidemic, to

examine the future of COVID-19 dynamics and control in Madagascar, which could be applicable

to other SSA countries.

Madagascar's demographic, economic, and health system profile is comparable to many

other SSA countries [23,25,26]. It shares most of the major infectious diseases of mainland Africa

(e.g. tuberculosis, malaria, respiratory infections, diarrheal diseases), and has recently endured

among the worst epidemics of plague and measles in decades [27,28]. Like other SSA countries,

Madagascar reported its first imported case relatively late, on March 20, 2020, and the

government implemented NPIs early in the epidemic (Table 1). Madagascar instituted a national

lockdown on March 23, 2020, three days before its first case attributed to local transmission.

Testing practices are also similar to those in other SSA countries, initially focusing on screening

for imported cases and eventually expanding to test contacts of known cases for local

transmission.

Our exercise shows that the current incidence of COVID-19 in Madagascar can be
explained by the early and effective implementation of NPIs and low case detection rates, both of
which are supported by strong anecdotal evidence. In contrast, arguments of regional-specific
epidemiology are based on correlational observations that have yet to be proven. This suggests
that the epidemic will grow in Madagascar, and similar countries in SSA, and that these
populations remain at risk of an impending health crisis. Our model indicates that, if NPIs remain
enforced at the level needed to explain current case burdens, nearly 50,000 lives could be saved.
Even with NPIs, 30% of the Malagasy population would become infected by March 2021, making
COVID-19 the leading killer in Madagascar over this epidemic period.

Case Detection
By July 2020, the simple forecast for an unmitigated epidemic predicts a daily incidence of 34,322
cases, which is nearly 500 times the reported daily incidence (Fig. 1A). Simply accounting for
detection rates between 0.1 - 1% results in predictions that closely approximate the reported daily
incidence of COVID-19 cases in Madagascar (Fig. 1B). Are these low levels of case detection
reasonable? For countries where per capita testing is over 100-fold higher than in Madagascar
(currently 79.1/100,000 population), it is estimated that less than 10% of COVID-19 cases have
been detected [29]. Though the precise case detection rates for Madagascar cannot be discerned
from available data, there are a number of indicators suggesting that these are lower than the
already low rates of Europe or the US.

First, case definitions in Madagascar may be stricter than elsewhere. In June 2020, about
12% of suspected cases tested were confirmed by RT-PCR in Madagascar compared to a
positivity rate of less than 5% in Europe and the US over the same period [30,31]. This suggests
strict criteria for test eligibility (e.g. requiring symptoms and known positive contacts) is being used
in Madagascar and many cases could potentially be missed. Further, strict diagnostic criteria may
be a result of the original testing policy of Madagascar, which required that suspected cases first
test positive with antibody-based rapid detection tests (RDTs) before being confirmed through
RT-PCR tests. The low probability of detection of antibodies early in the infectious period (i.e., the
first week of symptoms) and the high rate of false-negatives with RT-PCR later in the infectious
period (i.e., after 7-10 days post symptom onset) [32] create a short window for detection.

Second, the Madagascar health system itself is only receiving a portion of symptomatic
COVID-19 cases. The proportion of asymptomatic COVID-19 cases is estimated to be between
40 - 45% [33]. In Madagascar, surveys indicate that 40.2% of people with respiratory infection
symptoms seek healthcare [34], implying that over 50% of symptomatic COVID-19 infections may

not even enter a public health facility. For COVID-like symptoms, this rate could be much lower
given the stigma associated with the disease [11]. The combination of the high proportion of
asymptomatic cases and low health-seeking behaviors suggest that, even if health centers test
50% of symptomatic COVID-19 cases attending a health facility, this would detect less than 25%
of symptomatic cases.

Finally, there is limited diagnostic testing capacity in Madagascar, with RT-PCR testing
available in 5 laboratories across 3 major cities. It is unlikely that health facilities in rural areas of
the country, where nearly 50% of the population lives, are testing such a high percentage of cases.
We can account for all of these factors to estimate an upper bound of detection rates for
Madagascar (strict case definitions (0.3) x low proportion symptomatic (0.45) x low healthcare-
seeking behaviors (0.2) x limited testing infrastructure (0.25)) to reasonably explain a detection
rate in Madagascar of 1% or lower.

Reduced Transmission
A reduction in transmission rates of 30%, relative to an unmitigated scenario, can also explain the
daily case report rates of COVID-19 in Madagascar (Fig. 1C). This reduction could be the result
of NPI policies put in place in Madagascar or of innate characteristics affecting the epidemiology
of COVID-19 (e.g. baseline contact patterns, climate, etc.). NPIs were implemented within three
days after the first confirmed imported case of COVID-19 in the country (Table 1), the majority of
which focused on restricting intercity travel on roadways and included lockdowns in population
centers. In contrast, the UK instituted a partial-lockdown on March 23, 2020, 52 days after the
first confirmed case in the UK on January 31, 2020. The road system of Madagascar is highly
fragmented, with most travel on a limited number of paved national roads that run North-South
through the capital. Restricting travel on these roads has the potential to be highly effective in
reducing human mobility in Madagascar, and therefore the spread of COVID-19. Further, most
travel involves major population centers, particularly the capital city, Antananarivo [35]. These
cities had much more stringent NPIs put in place early in the epidemic, including city-wide
lockdowns and curfews (Table 1), and the targeted lockdown of these population centers could
have reduced spread to the rest of the country. While mobility data is not available for
Madagascar, other SSA countries have reported reductions in mobility ranging from 1.4% in
Zambia to 19% in Senegal compared to pre-NPI levels [36]. With a sparse road network that is
well regulated in Madagascar, 30% represents an obtainable reduction in contact rates.

Because NPIs were implemented early in the epidemic, their effects on transmission
cannot be disentangled from baseline contact patterns in the country, which may be lower than

those of Europe or the US. Nearly half (47.73%) of the Malagasy population lives in rural areas,

and most of the country is over 3 hours from a population center with more than 50,000 people

[37]. Therefore, baseline contact patterns in the rural areas of Madagascar may be reducing

disease spread in a way that is unidentifiable from the effects of NPIs.

Which path is Madagascar on?

The evidence presented here provides no indication that the epidemiology (e.g. R_0) of COVID-19

is fundamentally different in a fairly typical SSA country than elsewhere. We demonstrate that the

current trend in reported cases in Madagascar can be explained by its early stage in the epidemic,

combined with low detection rates and lower contact rates from NPIs (Fig. 2A). Understanding

how much of the discrepancy between predicted and reported case burdens is due to low

detection rates or NPIs has enormous implications for our expectations regarding the 'true' burden

of COVID-19 in Madagascar. For this, we explored different combinations of detection rates and

NPI efficacy that explain the observed trend in reported cases, together with associated

predictions of epidemic morbidity and mortality burdens (Figure 2). If the low number of reported

cases is due primarily to a low detection rate, we predict over 13 million people will be infected

with the virus if NPIs are not in place (Fig. 2C,D), imposing a huge burden on an already

weakened health system. On the other hand, if the low number of cases is due to a reduction in

contact patterns, the model predicts a lower total burden of approximately 8 million people

infected with the virus (Fig. 2C,D). If NPIs are driving these contact patterns and are responsible

for the lower-than-expected case burden, the lifting of these restrictions is very likely to lead to

an uncontrolled outbreak.

Although the global epidemic began several months ago, current infectious disease

models for Madagascar and other SSA countries rely on limited data, resulting in disparate

predictions. Pearson et al. (2020) predicted a similar epidemic size for Madagascar as our model

in an unmitigated scenario, with 75% of the population and nearly 100,000 deaths. In contrast, an

analysis led by the WHO [12] predicted a total case burden nearly one third of this size (26% of

the population) and only a fraction of COVID-19 related deaths (1,500). This study assumed that

the regional particularities of SSA will decrease disease transmission and fatality rates based on

country-specific proxies for these factors, such as climate, transportation networks, and contact

matrices. Importantly, this study only considered *reductions* in transmission via reduced risks of

exposure, with a maximum of 2.6% of the population of Madagascar at risk of exposure at any

one time. While socio-ecological context is necessary to understand disease transmission, our

exercise suggests that the difference between reported and predicted case burdens in SSA can

be just as easily explained by accounting for low detection rates and NPIs that reduce
interpersonal contact.
249

Conclusion
We do not currently have enough evidence to suggest that the epidemiology of COVID-
19 is different in Madagascar than elsewhere. The low number of reported cases can be explained
by low detection rates, late introduction, and early and effective implementation of NPIs. In
contrast to the theory of a salutary epidemiology, each of these explanations is supported by
strong anecdotal evidence (Table 2). As lockdowns are gradually lifted, other NPIs, such as
handwashing and social distancing, should be implemented to avoid a rapid growth in cases. The
public health system should remain prepared for an outbreak, with a peak of infections expected
between August and December depending on the transmission scenario (Fig. 2D). Even if the
current NPIs remain in place, the model suggests that COVID-19 could still cause over 50,000
deaths in Madagascar by March 2021, nearly twice as many deaths as are attributed to the current
leading cause of death due to infectious disease, diarrheal disease [38].
262

263 **Funding and Acknowledgements**

264 MVE was supported by a Graduate Research Fellowship (National Science Foundation). We
265 thank Tanjona Ramiadantsoa and Laura Cordier for their insights and comments on earlier drafts
266 of this manuscript.

267
268

Figures

Figure 1. The lower-than-expected daily incidence can be explained by detection rates of

0.1-1% or NPI efficiencies of 30% alone. Predicted epidemic trajectories for the unmitigated

scenario (A), range of detection rates (B), and range of NPI efficiencies (C). Results from 100

simulations are shown in A with the black line representing the median number of cases. Shaded

regions represent the 95% confidence intervals around the median in panels B and C. All

simulations began on the date of the first positive imported case in Madagascar, March 20, 2020.

The y-axis is plotted on the log10-scale.

Figure 2. Multiple combination of factors explain the low number of reported COVID-19 cases in Madagascar, with important implications for predictions of epidemic dynamics. Predicted A) daily reported cases (7 day average) as of June 22 2020, B) total infection burden after one year, and c) total fatality burden after one year in Madagascar at different combinations of NPI effectiveness and detection rates. The contour line corresponds to a parameter space where the median number of predicted cases from 25 simulations equals the daily reported cases (7 day average) on June 22 (71.71 cases). Shaded diamonds correspond to specific scenarios explored in panel D, illustrating the dynamics of detected infections, all infections, and cumulative deaths over the first year of the epidemic.

297   **Table 1.** Timeline of non-pharmaceutical interventions (NPIs) implemented in Madagascar.

Date	Policy / Intervention / Program	Geographic extent (Region)
By March 19	Allowing the remaining people outside of the country and willing to return to Madagascar to come back	National level
March 20	Beginning of the epidemic in Madagascar with 3 initial imported cases announced	Analamanga*
March 20	Interruption of all international and regional flights from the outside of the country	National level
March 21	Following-up and testing all passengers entering Madagascar for the last 14 days for COVID-19	National level
March 23	Lockdown; curfew; interruption of all public transportation (ground and air travel) connecting Antananarivo and Toamasina to the other regions with establishment of health barrier at all national roads; prohibition of all meeting for more that 50 individuals	Analamanga and Atsinanana**
March 26	Reception of 20000 Antibody RDT kits for COVID-19 testing	NA
March 31 to April 02	Mass Antibody RDT testing for all passengers entering Madagascar on March 11-19	Analamanga and Atsinanana
April 03	Adding the lockdown to Fianarantsoa after detection of COVID-19 confirmed cases	Haute-Matsiatra***, Analamanga and Atsinanana
April 05	Continuing lockdown and curfew	Analamanga, Atsinanana and Haute-Matsiatra
April 07-09	Temporary opening of national transportation by taxi-brousse to allow people from the other regions but blocked in other cities to return home	National level
April 17	Partial lifting of lockdown, which allow people to go out, as well as taxi and bus to work from 6:00 a.m. to 1:00 p.m; curfew maintained; social distancing and mandatory wearing of mask for all person going out	Analamanga, Atsinanana and Haute-Matsiatra
April 20	Launching the COVID Organics tisane based on Artemisia	NA
April 22	All classes preparing official exam resume	National level
May 04	All previous measures maintained, and adding the Alaotra-Mangoro region; church could receive no more than 50 persons	Analamanga, Atsinanana, Haute-Matsiatra and Alaotra-Mangoro****
May 04	Church could receive no more than 200 persons	The remaining 18 regions
May 17	All previous measures maintained	Analamanga, Atsinanana, Haute-Matsiatra and Alaotra-Mangoro
May 31	Progressive lifting of lockdown allowing people to work from 6:00 a.m to 3:00 p.m	Analamanga
May 31	Toamasina region totally locked to the other location, all classes interrupted, and people can work from 6:00 a.m. to 1:00 p.m	Atsinanana
May 31	All previous measures maintained	Alaotra-Mangoro
May 31	Daily life return to the normal because COVID-19 is controlled in Fianarantsoa	Haute-Matsiatra

| June 14 | Progressive lifting of lockdown allowing people to work from 6:00 a.m to 5:00 p.m, and public transportation until 7:00 p.m | Analamanga |
| June 14 | Progressive lifting of lockdown from 6:00 a.m to 3:00 p.m | Atsinanana and Alaotra-Mangoro |

* (Antananarivo)
** (Toamasina)
*** (Fianarantsoa)
**** (Moramanga, Ambatondrazaka, Anosibe an'Ala)

Table 2. Summary of evidence supporting or opposing three possible explanations for the low number of reported cases of COVID-19 in Madagascar.

	Supporting	Opposing
Low detection rates	- High proportion of asymptomatic cases[33] - Strict testing criteria - Low healthcare seeking rates for acute respiratory infections[34] - Diagnostic practices that limit the window of detection	- Recent evaluation of health system preparedness via the International Health Regulations meant health systems were on high alert for an outbreak [20]
Epidemiological differences	- Trained-immunity due to vaccinations or high prevalence of endemic disease could increase population's resistance to infection [14] - Transmission rate may be lower in sparsely populated areas [13] - Virus survival is lower in humid, warm environments	- Limited role for climate during pandemic phase of the outbreak [16] - Past influenza outbreaks were not limited by sparse transport networks in SSA [17]
Early and effective NPIs	- Lockdown in population centers implemented three days after first imported case - Limiting travel on fragmented paved road network can easily disrupt within-country movement	

References

1   Clark A, Jit M, Warren-Gash C, *et al.* Global, regional, and national estimates of the
population at increased risk of severe COVID-19 due to underlying health conditions in
2020: a modelling study. *The Lancet Global Health* 2020;**0**. doi:10.1016/S2214-
109X(20)30264-3

2   El-Sadr WM, Justman J. Africa in the Path of Covid-19. *New England Journal of Medicine*
Published Online First: 17 April 2020. doi:10.1056/NEJMp2008193

3   Massinga Loembé M, Tshangela A, Salyer SJ, *et al.* COVID-19 in Africa: the spread and
response. *Nature Medicine* 2020;:1–4. doi:10.1038/s41591-020-0961-x

4   Nkengasong JN, Mankoula W. Looming threat of COVID-19 infection in Africa: act
collectively, and fast. *Lancet* 2020;**395**:841–2. doi:10.1016/S0140-6736(20)30464-5

5   Rosenthal PJ, Breman JG, Djimde AA, *et al.* COVID-19: Shining the Light on Africa. *The*
American Journal of Tropical Medicine and Hygiene 2020;**102**:1145–8.
doi:10.4269/ajtmh.20-0380

6   Taboe BH, Salako VK, Ngonghala CN, *et al.* Predicting COVID-19 spread and public health
needs to contain the pandemic in West-Africa. *medRxiv* 2020;:2020.05.23.20111294.
doi:10.1101/2020.05.23.20111294

7   Africa Centers for Disease Control and Prevention. Outbreak Brief 22: COVID-19 Pandemic
– 16 June 2020. 2020. https://africacdc.org/download/outbreak-brief-22-covid-19-pandemic-
16-june-2020/ (accessed 24 Jun 2020).

8   Africa Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19).
2020. https://africacdc.org/covid-19/

9   Kavanagh MM, Erondu NA, Tomori O, *et al.* Access to lifesaving medical resources for
African countries: COVID-19 testing and response, ethics, and politics. *The Lancet*
2020;**395**:1735–8. doi:10.1016/S0140-6736(20)31093-X

10   Requejo J, Diaz T, Park L, *et al.* Assessing coverage of interventions for reproductive,
maternal, newborn, child, and adolescent health and nutrition. *BMJ* 2020;**368**.
doi:10.1136/bmj.l6915

11   Logie CH. Lessons learned from HIV can inform our approach to COVID-19 stigma. *Journal*
of the International AIDS Society 2020;**23**:e25504. doi:10.1002/jia2.25504

12   Cabore JW, Karamagi HC, Kipruto H, *et al.* The potential effects of widespread community
transmission of SARS-CoV-2 infection in the World Health Organization African Region: a
predictive model. *BMJ Global Health* 2020;**5**:e002647. doi:10.1136/bmjgh-2020-002647

13   Diop BZ, Ngom M, Biyong CP, *et al.* The relatively young and rural population may limit the
spread and severity of COVID-19 in Africa: a modelling study. *BMJ Global Health*
2020;**5**:e002699. doi:10.1136/bmjgh-2020-002699

14 Netea MG, Domínguez-Andrés J, Barreiro LB, *et al.* Defining trained immunity and its role in
health and disease. *Nature Reviews Immunology* 2020;**20**:375–88. doi:10.1038/s41577-
020-0285-6

15 O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against
COVID-19? *Nature Reviews Immunology* 2020;**20**:335–7. doi:10.1038/s41577-020-0337-y

16 Baker RE, Yang W, Vecchi GA, *et al.* Susceptible supply limits the role of climate in the
early SARS-CoV-2 pandemic. *Science* Published Online First: 18 May 2020.
doi:10.1126/science.abc2535

17 Katz MA, Schoub BD, Heraud JM, *et al.* Influenza in Africa: Uncovering the Epidemiology of
a Long-Overlooked Disease. *J Infect Dis* 2012;**206**:S1–4. doi:10.1093/infdis/jis548

18 Moore J. What African Nations Are Teaching the West About Fighting the Coronavirus. The
New Yorker. 2020.https://www.newyorker.com/news/news-desk/what-african-nations-are-
teaching-the-west-about-fighting-the-coronavirus (accessed 2 Jul 2020).

19 Senghore M, Savi MK, Gnangnon B, *et al.* Leveraging Africa's preparedness towards the
next phase of the COVID-19 pandemic. *The Lancet Global Health* 2020;**8**:e884–5.
doi:10.1016/S2214-109X(20)30234-5

20 Ihekweazu C, Agogo E. Africa's response to COVID-19. *BMC Medicine* 2020;**18**:151.
doi:10.1186/s12916-020-01622-w

21 World Health Organization. WHO urges caution as countries in Africa ease lockdowns.
Regional Office for Africa. 2020.https://www.afro.who.int/news/who-urges-caution-countries-
africa-ease-lockdowns (accessed 2 Jul 2020).

22 Roche B, Garchitorena A, Roiz D. Optimal strategies for quarantine stopping in France.
General expected patterns of strategies focusing on contact between age groups. *medRxiv*
2020;:2020.04.21.20073932. doi:10.1101/2020.04.21.20073932

23 Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact
surveys and demographic data. *PLOS Computational Biology* 2017;**13**:e1005697.
doi:10.1371/journal.pcbi.1005697

24 Kissler SM, Tedijanto C, Goldstein E, *et al.* Projecting the transmission dynamics of SARS-
CoV-2 through the postpandemic period. *Science* 2020;**368**:860–8.
doi:10.1126/science.abb5793

25 Pearson CA, Schalkwyk CV, Foss AM, *et al.* Projected early spread of COVID-19 in Africa
through 1 June 2020. *Eurosurveillance* 2020;**25**:2000543. doi:10.2807/1560-
7917.ES.2020.25.18.2000543

26 Walker PGT, Whittaker C, Watson OJ, *et al.* The impact of COVID-19 and strategies for
mitigation and suppression in low- and middle-income countries. *Science* Published Online
First: 12 June 2020. doi:10.1126/science.abc0035

27 Bonds MH, Ouenzar MA, Garchitorena A, *et al.* Madagascar can build stronger health
systems to fight plague and prevent the next epidemic. *PLOS Neglected Tropical Diseases*
2018;**12**:e0006131. doi:10.1371/journal.pntd.0006131

28 Mahase E. Measles cases at highest point since 2006 as outbreaks continue to spread.
BMJ 2019;**366**. doi:10.1136/bmj.l5141

29 Havers FP, Reed C, Lim TW, *et al.* Seroprevalence of Antibodies to SARS-CoV-2 in Six
Sites in the United States, March 23-May 3, 2020. *medRxiv* 2020;:2020.06.25.20140384.
doi:10.1101/2020.06.25.20140384

30 Madagascar Ministry of Health. COVID-19 - Madagascar. 2020.
https://covid19mg.madatsara.com/en

31 John Hopkins University. Johns Hopkins COVID-19 Testing Insights Initiative. 2020.
https://coronavirus.jhu.edu/testing

32 Kucirka LM, Lauer SA, Laeyendecker O, *et al.* Variation in False-Negative Rate of Reverse
Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since
Exposure. *Ann Intern Med* Published Online First: 13 May 2020. doi:10.7326/M20-1495

33 Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative
Review. *Annals of Internal Medicine* 2020;:M20-3012. doi:10.7326/M20-3012

34 UNICEF. Madagascar Multiple Indicator Cluster Survey version 6. 2018.
https://mics.unicef.org/

35 Ihantamalala FA, Herbreteau V, Rakotoarimanana FMJ, *et al.* Estimating sources and sinks
of malaria parasites in Madagascar. *Nature Communications* 2018;**9**:3897.
doi:10.1038/s41467-018-06290-2

36 Google. COVID-19 Community Mobility Reports. 2020.
https://www.google.com/covid19/mobility/ (accessed 14 Jun 2020).

37 Weiss DJ, Nelson A, Gibson HS, *et al.* A global map of travel time to cities to assess
inequalities in accessibility in 2015. *Nature* 2018;**553**:333–6. doi:10.1038/nature25181

38 Roth GA, Abate D, Abate KH, *et al.* Global, regional, and national age-sex-specific mortality
for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis
for the Global Burden of Disease Study 2017. *The Lancet* 2018;**392**:1736–88.
doi:10.1016/S0140-6736(18)32203-7